Skip to main content
رجوع
CTKB logo

Cytek Biosciences, Inc.

جودة البيانات: 100%
CTKB
NASDAQ Healthcare Medical - Devices
KWD 4.60
▼ KWD 0.03 (-0.65%)
القيمة السوقية: 591.33M
نطاق اليوم
KWD 4.52 KWD 4.75
نطاق 52 أسبوعًا
KWD 2.37 KWD 6.18
حجم التداول
536,453
متوسط 50 يوم / 200 يوم
KWD 4.71 / KWD 4.27
الإغلاق السابق
KWD 4.63

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -8.9 0.2
P/B 1.7 3.0
ROE % -18.1 3.6
Net Margin % -33.0 3.8
Rev Growth 5Y % 12.0 9.9
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 6.00 +30.4%
ربحية السهم المستقبلية
-KWD 0.21
الإيرادات المقدّرة
208.26M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 -KWD 0.08
-KWD 0.08 – -KWD 0.08
258.90M 1
FY2028 -KWD 0.05
-KWD 0.05 – -KWD 0.05
246.31M 2
FY2027 -KWD 0.14
-KWD 0.17 – -KWD 0.09
222.89M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 -KWD 0.02 -KWD 0.01 +50.0%
2025-11-05 KWD 0.01 -KWD 0.01 -200.0%
2025-08-06 -KWD 0.02 KWD 0.01 +150.0%
2025-05-08 -KWD 0.04 -KWD 0.09 -125.0%
2025-02-27 KWD 0.05 KWD 0.07 +40.0%
2024-11-05 KWD 0.00 KWD 0.01 +166.7%
2024-08-06 -KWD 0.03 -KWD 0.08 -166.7%
2024-05-08 -KWD 0.05 -KWD 0.05 0.0%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 12.02% annually over 5 years — strong growth
Debt/Equity of 0.10 — conservative balance sheet
Negative free cash flow of -8.77M
Revenue growth is decelerating — 1Y growth trails 5Y average by 11.50%
Capital efficient — spends only 2.03% of revenue on capex

النمو

Revenue Growth (5Y)
12.02%
Revenue (1Y)0.52%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-18.05%
ROIC-8.08%
Net Margin-33.02%
Op. Margin-20.04%

الأمان

Debt / Equity
0.10
Current Ratio5.04
Interest Coverage-85.20

التقييم

P/E Ratio
-8.89
Forward P/EN/A
P/B Ratio1.73
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.52% Revenue Growth (3Y) 2.17%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 12.02% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 201.49M Net Income (TTM) -66.54M
ROE -18.05% ROA -14.42%
Gross Margin 51.84% Operating Margin -20.04%
Net Margin -33.02% Free Cash Flow (TTM) -8.77M
ROIC -8.08% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.10 Current Ratio 5.04
Interest Coverage -85.20
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8.89 Forward P/E N/A
P/B Ratio 1.73 P/S Ratio 2.93
PEG Ratio -0.01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2.84 Fwd Earnings Yield N/A
FCF Yield -1.48%
Market Cap 591.33M Enterprise Value 533.50M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 201.49M 200.45M 193.02M 164.04M 127.95M
Net Income -66.54M -6.02M -12.15M 2.58M 3.00M
EPS (Diluted) -0.52 -0.05 -0.09 0.02 0.03
Gross Profit 104.46M 111.11M 109.43M 100.97M 79.14M
Operating Income -40.38M -20.52M -27.85M -1.80M 9.16M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 461.54M 499.50M 494.46M 519.48M 463.31M
Total Liabilities 119.80M 103.76M 101.39M 93.93M 57.92M
Shareholders' Equity 341.74M 395.74M 393.06M 425.30M 405.04M
Total Debt 33.02M 17.02M 14.14M 18.09M 0.0
Cash & Equivalents 90.85M 98.72M 167.30M 296.60M 364.62M
Current Assets 392.00M 396.45M 392.06M 454.02M 431.73M
Current Liabilities 77.80M 67.66M 56.23M 49.04M 33.18M